Bengaluru, Karnataka, India, Sep 18, 2017
This is to inform you that the US FDA inspected our Active Pharmaceutical Ingredients (API) manufacturing facility in Vishakhapatnam, Andhra Pradesh from Sep 11 to 15, 2017 and completed the audit without any observations. No form 483 was issued. The successful audit of this facility reflects our strong commitment to cGMP compliance at our manufacturing facilities.
– Company Spokesperson
Download Company Statement
